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Hospitals have made substantial investments in advertising for cancer services in the past two 
decades, totalling over US$200 million in 2016 alone.1,2 Advertisements promoting cancer 
centres are unavoidable in the USA. They hang on highway billboards and on air during prime-
time programming. Some advertisements claim superior outcomes, others highlight access to 
clinical trials, and many present heart-warming patient stories that might be non-representative 
of actual outcomes.3 Data suggest that patients are highly aware of advertisements and are 
likewise influenced by them.4 
Decades of research have shown wide and consistent variations in cancer care outcomes between 
US hospitals.5, 6, Although patients might wish to select their cancer care provider based on 
objective measures of cancer care quality and outcomes,7,8 few measures are publicly available. 
Advertising is designed to improve cancer centre recognition and attract patients in an 
increasingly competitive environment. It has the potential to provide valuable information about 
screening and treatment options, and it could benefit patients by attracting them to hospitals with 
the best outcomes. However, if hospital advertising for cancer services is not correlated with 
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patient outcomes, information shared through advertising might mislead patients and generate 
inaccurate expectations of treatment benefit.9 
We did an analysis to evaluate whether advertising spending for a hospital's cancer services was 
associated with long-term survival outcomes of patients with cancer treated in those centres. For 
the measures of advertising spending and long-term survival, we applied methods that have been 
described previously.9,, 10 We captured hospital advertising spending for cancer services in 2014 
across six different US media outlets (television, magazines, radio, newspapers, billboards, and 
the Internet), using data from the media-monitoring agency Kantar Media (New York, NY, 
USA).9 Medicare fee-for-service 100% research-identifiable files were used to determine 
hospital risk-adjusted 5-year mortality ratios, including cases from 2011–12.10 We included the 
top 50 hospitals (or sets of hospitals) in terms of their advertising spending, accounting for over 
89% of the $173 million spent on cancer centre advertising in 2014. 
The primary test of association was a linear regression, with advertising spending as the 
predictor. The outcome was a risk-adjusted mortality ratio that was determined by dividing the 
observed number of deaths by an expected number. A risk-adjusted mortality ratio below 1 
indicates that a hospital performed better than expected, whereas a ratio greater than 1 means a 
hospital had higher mortality than expected. In total, we used four models to assess the 
relationship between advertising spending and risk-adjusted mortality. This study was deemed 
exempt research by the institutional review board of Memorial Sloan Kettering Cancer Center 
(New York, NY). The Centers for Medicare & Medicaid Services and Kantar Media granted 
data-use approvals. Additional methodological details can be found in the appendix (pp 1–2). 
For the top 50 hospital advertisers, the median number of fee-for-service Medicare patients with 
cancer treated was 764 (range 93–5945). Spending for advertising that promoted cancer services 
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was unevenly distributed across hospitals (figure). Median spending was $305 900. The 50th 
hospital spent $106 300, the average hospital spent $3 064 600, and the top advertising 
spender—Cancer Treatment Centers of America—spent more than the other 49 hospitals 
combined, totalling $101 740 900. 5-year hospital risk-adjusted mortality ratio for patients with 
cancer ranged from 0·83 to 1·13, meaning hospitals' mortality ratio ranged from 17% (0·83) 
below expected to 13% (1·13) higher than expected. Results between the four models were fairly 
inconsistent. Some of the models found a positive relation between advertising spending and 
survival outcomes; other models found a negative relation. For two of the four models, this 
relationship was not significant. None of the models had an R2 greater than 38%, indicating that 
hospital advertising did not account for most of the variability in hospital survival outcomes. The 
figure shows the full explanation of the model results. A list of all hospitals with spending, 
volume, and survival outcomes is available in the appendix (pp 3–4). 
We found little evidence that the cancer centres to which people were most likely to be exposed 
through advertisements were the cancer centres with the best patient outcomes. There was 
considerable variation in both advertising spending and survival outcomes among the top 50 
hospital advertisers. Some hospitals in our sample with excellent outcomes did not have 
particularly high advertising spending, and the highest-spending set of hospitals—operating as 
Cancer Treatment Centers of America—had poorer patient outcomes than all other hospitals in 
our sample. Patients might be inadvertently pursuing treatment choices that do not align with 
their intentions or preferences by assuming that advertising across national media is indicative of 
high-quality cancer treatment. Over the past decade, cancer centres have markedly increased the 
amount of consumer-directed advertising spending. Assuming current trends continue, cancer-
centre advertising is likely to constitute a major source of patient information that might 
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influence decisions about where patients with cancer seek treatment. This effect would be good 
for patients if advertising were predictive of improved patient outcomes. However, our findings 
suggest that the relation is inconsistent and not particularly strong, with many outliers. 
Some limitations should be considered when interpreting our findings. For long-term survival, 
we only included fee-for-service Medicare beneficiaries, and the generalisability of this outcome 
to other patients is unknown. Advertising spending totals did not include spending for social 
media, which has been widely adopted by US hospitals as a means to support hospitals' 
reputations and attract patients. We also did not have data available on the content of cancer 
centre advertisements, and we were thus unable to distinguish between advertisements promoting 
specific cancer therapies and advertisements promoting general cancer centre reputations. Our 
analysis was limited to cancer centre advertising in the USA, but the USA has the highest health-
care spending in the world, and in the past two decades there has been a marked growth in 
spending for health-care advertising.1 
Hospital advertising for cancer services continues to increase in the USA, and patients have more 
options for where to seek cancer care. However, cancer care quality remains uneven. Our 
findings suggest that cancer care advertising is not reliably valuable for patients as a surrogate of 
cancer care quality. The absence of correlation underscores the need for publicly available 
objective data on cancer centres' patient outcomes and other measures of quality that can be 
easily accessed and interpreted by patients to aid them in decision making. Patients, clinicians, 
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Scatterplots of hospitals' advertising spending for cancer services in 2014, compared with 
risk-adjusted 5-year mortality for fee-for-service Medicare beneficiaries beginning 




Appendix A. Methodological details  
We evaluated whether hospitals’ advertising spending was associated with long-term 
survival among cancer patients treated in those centers. For both measures, we applied 
previously described methods.1,2 We captured hospital advertising spending for cancer services 
in 2014 using data from the media-monitoring agency Kantar Media (New York, New York). We 
included advertising by centers with the terms “cancer,” “oncology,” “radiation,” or another 
cancer therapy (e.g., proton therapy) in their name or advertisement.2  Free-standing clinics and 
solo outpatient centers were excluded.  
Medicare Fee-for-Service (FFS) 100% Research Identifiable Files were used to 
determine hospital risk-adjusted five-year mortality ratios, including cases from 2011-12. Each 
case had new claims for cancer care after a year (or more) without a claim for a cancer 
diagnosis, and mortality data through 2017.1 When multiple hospitals were involved under one 
advertising campaign, we pooled their outcomes weighted by the number of patients treated at 
each hospital. We included the top 50 hospitals (or sets of hospitals) in terms of their advertising 
spending, accounting for over 89% of the 173 million dollars spent on advertising in 2014.  
Statistical analysis  
The primary test of association was a linear regression, with advertising spending as the 
predictor. The outcome was a risk-adjusted mortality ratio which was determined by dividing the 
observed number of deaths by an expected number. In brief, the 3M Clinical Risk Group (CRG) 
risk adjustment model in combination with adjustments for age and median income level of the 
zip code of residence serve to adjust for differences in patient severity and population 
demographics. A risk-adjusted mortality ratio below one indicates that a hospital performed 
better than expected, where a ratio greater than one means a hospital had higher mortality than 
what was expected. The R-squared from the regression model was used to see how well 
advertising spending explained outcomes. We conducted additional analyses that included a log 
transformation of the x variable (i.e., spending) and weighting of the outcome (y) variable (i.e., 
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risk- adjusted five-year mortality) by the volume of patients at the hospital. In total, there were 
four models used to assess the relationship between advertising spending and risk-adjusted 
mortality. This study was deemed exempt research by the institutional review board of Memorial 
Sloan Kettering Cancer Center. The Centers for Medicare & Medicaid Services and Kantar 
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spend Hospital advertiser1 State(s)2 
Advertising 
spend ($) in 
thousands3 






1 Cancer Treatment Centers of America 
AZ, GA, IL, OK, 
PA 101741 506 1.13 
2 MD Anderson Cancer Center AZ, NJ, TX 15155 7587 0.90 
3 Memorial Sloan Kettering Cancer Center NY 9086 5945 0.83 
4 Fox Chase Cancer Center PA 3520 1233 0.90 
5 Huntsman Cancer Institute UT 2178 901 1.03 
6 Sutter Cancer Center CA 2089 2026 0.97 
7 Dana-Farber Cancer Institute MA 1836 2993 0.94 
8 Seattle Cancer Care Alliance WA 1821 1591 0.97 
9 Winthrop NYCyberKnife Center NY 1336 1162 0.98 
10 CDH Proton Center IL 1256 1910 0.89 
11 H Lee Moffitt Cancer Center FL 1113 2794 0.87 
12 University of Florida FL 1113 1839 0.94 
13 James Cancer Hospital OH 962 1646 0.96 
14 Edward Cancer Center IL 864 720 1.01 
15 Swedish Cancer Institute WA 663 1818 0.96 
16 Smilow Cancer Hospital CT 573 2235 0.97 
17 Siteman Cancer Center MO 486 2844 0.97 
18 University of MD Greenebaum Cancer Center MD 396 817 1.02 
19 Karmanos Cancer Institute MI 386 971 0.96 
20 Scripps Proton Therapy Center CA 363 1965 0.97 
21 Northside Hospital Cancer Institute GA 340 1712 1.03 
22 Cancer Institute of NJ NJ 338 171 1.01 
23 Morristown Medical Center NJ 332 1325 0.98 
24 Houston Methodist Cancer Center TX 322 93 1.04 
25 NYU Cancer Institute NY 306 1630 0.87 
26 HealthEast CyberKnife Center MN 305 151 1.07 
27 
University of Chicago Medicine Comprehensive   
   Cancer Center IL 303 1351 0.93 
28 Hartford HealthCare Cancer Institute CT 266 2514 0.99 
29 Abramson Cancer Center PA 264 3047 0.92 
30 Memorial Cancer Institute FL 255 433 0.97 
31 City of Hope Cancer Center CA 241 1178 0.87 
32 University of KS Cancer Center  KS 224 1851 1.01 
33 Christus Schumpert Cancer Treatment Center LA 218 559 1.02 
34 Sylvester Comprehensive Cancer Center FL 197 659 0.93 
35 University Hospitals Seidman Cancer Center OH 194 1414 0.93 
36 UPMC Cancer Centers PA 184 3949 0.97 
37 Edwards Comprehensive Cancer Center WV 172 389 0.98 
38 Mary Bird Perkins Cancer Center LA 171 1454 1.04 
39 John Theurer Cancer Center NJ 165 1870 0.93 
40 Kettering Cancer Care OH 164 709 0.96 
41 Intermountain Cancer Center UT 156 679 1.03 
42 St Peters Hospital Cancer Care Center NY 150 957 0.97 
43 Stephenson Cancer Center OU Medical OK 146 900 0.99 
44 USC Norris Comprehensive Cancer Center CA 135 263 1.00 
45 Upstate Cancer Center NY 133 767 1.04 




1Advertisers include hospitals or set of hospitals involved under one advertising campaign. 
2These are the states for the hospitals that were used to calculate the five-year risk-adjusted mortality ratio for that advertiser.  
3Advertising spend for 2014. 
4Volume is summed over the set of hospitals involved under one advertising campaign. 
5Hospital risk-adjusted mortality ratio for patients with FFS Medicare coverage beginning treatment in 2011-2012. 
 
47 Providence Cancer Center AK, OR, WA 127 5486 0.98 
48 Reid Cancer Center IN 124 531 1.07 
49 Montefiore Einstein Center for Cancer Care NY 120 951 1.00 
50 Inova Comprehensive Cancer & Research Institute VA 106 2580 1.01 
